Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock BiotechFRA:6BU0 -3.85%64 Days Inventory is 154.28 as of Mar. 2026, which is 24% below its 10-year median of 202.22. GuruFocus rates FRA:6BU0 with a GF Score™ of 64/100 and a GF Value™ of €6.13 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 180 Medical Diagnostics & Research companies, Burning Rock Biotech ranks worse than 80% on this metric.
The historical rank and industry rank for Burning Rock Biotech's Days Inventory or its related term are showing as below:
FRA:6BU0'
s Days Inventory Range Over the Past 10 Years
Min: 134.33 Med: 202.22 Max: 264.18
Current: 155.7
During the past 9 years, Burning Rock Biotech's highest Days Inventory was 264.18. The lowest was 134.33. And the median was 202.22.
FRA:6BU0's Days Inventory is ranked worse than 80% of 180
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.86
vs FRA:6BU0: 155.70
Burning Rock Biotech's Days Inventory
declined
from Mar. 2025 (154.32) to Mar. 2026 (154.28).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Burning Rock Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.59.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Burning Rock Biotech's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.47.
Burning Rock Biotech (FRA:6BU0) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Burning Rock Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Burning Rock Biotech's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Burning Rock Biotech Days Inventory Related Terms
Burning Rock Biotech Days Inventory Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6BU0 vs XGN, IDXG, PRPO: Days Inventory Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Days Inventory distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (FRA:6BU0) has a Days Inventory of 154.28 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Burning Rock Biotech and its competitors. This is 24% below median its historical median of 202.22. Over the past decade, Burning Rock Biotech's Days Inventory has ranged from 134.33 to 264.18. According to the industry distribution chart, Burning Rock Biotech ranks #144 out of 180 companies in the Medical Diagnostics & Research industry, placing it in the top 80%.
Is Burning Rock Biotech's Days Inventory too high?
Burning Rock Biotech's current Days Inventory of 154.28 is 24% below median its 10-year median of 202.22. Over the past 10 years, this metric has ranged from a low of 134.33 to a high of 264.18. The Medical Diagnostics & Research industry median Days Inventory is 64.86. Burning Rock Biotech's value of 154.28 is 137.9% above this industry median. Based on the distribution chart, Burning Rock Biotech ranks #144 out of 180 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Days Inventory compare to XGN and IDXG?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #144 out of 180 companies for Days Inventory. This places Burning Rock Biotech in the lower half of its industry. The industry median Days Inventory is 64.86. Burning Rock Biotech's value of 154.28 is 137.9% above this benchmark. Historically, Burning Rock Biotech's own Days Inventory has ranged from 134.33 to 264.18 over the past decade. While the company's 10-year median is 202.22 vs. the industry median of 64.86, Burning Rock Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 64.86, based on 180 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Burning Rock Biotech's current Days Inventory of 154.28 is 137.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 64.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current Days Inventory is 154.28, which is 24% below median its own 10-year median of 202.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (FRA:6BU0) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.13, compared to a current price of €8.75 — trading 42.7% above its estimated fair value. The current Days Inventory is 154.28, which is 24% below median its 10-year median of 202.22 and 137.9% above the Medical Diagnostics & Research industry median of 64.86. Burning Rock Biotech's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Burning Rock Biotech (FRA:6BU0), the current Days Inventory is 154.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (FRA:6BU0) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of €8.75 is trading 42.7% above its estimated GF Value™ of €6.13.
GuruFocus considers Burning Rock Biotech to be Significantly Overvalued.
Key valuation signals for FRA:6BU0:
Days Inventory: 154.28 (24% below median its 10-year median of 202.22)
GF Value™: €6.13 vs. price of €8.75 (42.7% above fair value)
Industry Position: 137.9% above the Medical Diagnostics & Research median (#144 of 180)
No single metric tells the full story. See the FRA:6BU0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
64GF Score
Get the complete analysis for FRA:6BU0
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6BU0 has been successfully added to your 
